Neurology and CNS Peptides

Dr. William Alden 5 min read

William Alden, MD, PhD | Medical Peptide & Fatty Acid Series

Neurology and CNS Peptides

By William Alden, MD, PhD | Medical Peptide, Regenerative & Fatty Acid Series

Neuroactive peptides span FDA-approved therapies for rare neurologic disease and severe pain on one hand, and a group of nootropic peptides used abroad (and sometimes compounded) on the other. I separate the well-validated from the experimental so that patients receive an accurate picture of evidence and regulatory status.

Key Agents in This Class

Levacetylleucine (Aqneursa). An N-acetyl-leucine derivative that modulates lysosomal and autophagy pathways. First FDA-approved treatment for the neurological manifestations of Niemann-Pick disease type C.

Ziconotide (Prialt). A synthetic ω-conotoxin from cone-snail venom that blocks N-type voltage-gated calcium channels on dorsal-horn neurons, interrupting nociceptive transmission. FDA-approved as an intrathecal non-opioid analgesic for severe refractory chronic pain; does not produce opioid-type tolerance.

Semax, Selank, DSIP, dihexa. Nootropic and neuroactive peptides. Semax (ACTH fragment analog) and Selank (tuftsin analog) are approved in Russia for stroke, cognitive, and anxiety indications; they occupy gray-zone or Category 1 status in the U.S. DSIP has been studied for sleep architecture. Dihexa is a potent angiotensin-IV analog that promotes synaptogenesis in animal models but lacks human trials.

Cerebrolysin. A mixture of low-molecular-weight neurotrophic peptides derived from porcine brain. Used abroad for stroke and dementia recovery; not FDA-approved in the United States.

Evidence and Regulatory Status

Levacetylleucine and ziconotide have defined, important, FDA-approved roles. The nootropic peptides rest largely on non-U.S. approvals, observational series, or preclinical data and are not FDA-approved. Compounding status for several has been affected by the 2026 reclassifications. Patients should be told clearly which agents have robust U.S. regulatory validation and which do not.

Frequently Asked Questions
Is ziconotide an opioid?

No. It is a non-opioid intrathecal analgesic that works through calcium-channel blockade and does not cause the tolerance or respiratory-depression profile of opioids.

No. They are approved and used in Russia and certain other countries but are not FDA-approved.

Preclinical only at present. Animal data on synaptogenesis and memory are intriguing, but no completed human efficacy trials exist.

Is thymosin alpha-1 FDA-approved?

It is approved and widely used in many countries but is not FDA-approved in the United States.

Most have limited controlled human data. The mechanistic rationale is interesting, but claims of broad clinical benefit outrun the current evidence base.

Nominations were withdrawn, removing them from Category 2, yet they were not added to Category 1 or the 503A bulks list. Compounding therefore remains a regulatory gray zone pending further PCAC review.

Clinical Perspective

This class pairs genuinely valuable approved therapies with an experimental fringe. Telling patients honestly which is which—and matching expectations to the strength of the evidence—is essential.

Read more about this: [Reproductive Health: GnRH Agents and Fertility Peptides] and [Obstetric and Oxytocin Peptides].

About the Author
William “Wes” Alden, MD, PhD, is a physician-scientist and internist whose career spans academic medicine, federal clinical research, community healthcare, and medical philanthropy. His work sits at the intersection of laboratory science and bedside care, and his writing consistently returns to one theme: regenerative and metabolic therapies deserve both open-minded use and rigorous scientific and regulatory scrutiny. This series surveys the major categories of therapeutic peptides and healthful fatty acids, one blog at a time, with an emphasis on honest evidence and clear regulatory status.

Important Disclosure and Disclaimer
This content is for general education and reflects Dr. Alden’s professional perspective. It is not medical advice and does not create a doctor-patient relationship. Individual results vary, and many agents discussed are not FDA-approved for the uses described. Several peptides are not FDA-approved and have an evolving federal compounding status; products labeled for research use only are never appropriate for use in people. Most fatty acids discussed are foods or dietary supplements and are not FDA-approved to treat any condition. Any peptide or compounded agent should be used only through a licensed provider, with appropriately sourced pharmaceutical-grade material. Readers should consult a qualified healthcare professional about their own situation before pursuing any treatment.


Educational content reflecting Dr. Alden’s professional perspective. Not medical advice. Several agents named are not FDA-approved and some have an evolving compounding status. See the full disclosure accompanying this series.